Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + docetaxel + doxorubicin + fluorouracil
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This appears to be a combination of four chemotherapy drugs that are commonly used in breast cancer treatment. However, based on the available information, these four drugs are not typically administered together as a single regimen. Instead, they are used in two separate regimens: TAC (docetaxel, doxorubicin, and cyclophosphamide) and FAC (fluorouracil, doxorubicin, and cyclophosphamide). These regimens are often compared in clinical trials for the treatment of breast cancer.
02
Targets
DNATS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))MicrotubuleTOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on cyclophosphamide + docetaxel + doxorubicin + fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + docetaxel + doxorubicin + fluorouracil.